The first infant has been screened in the THRIVE trial evaluating the VIASKIN Peanut Patch as an early intervention for peanut allergy.
Douglas Mack, MD, MSc, FRCPC
Advertisement
Douglas Mack, MD, MSc, FRCPC, pediatric allergist and assistant clinical professor at McMaster University.
Articles by Douglas Mack, MD, MSc, FRCPC
THRIVE has begun screening infants aged 6 to 12 months to evaluate whether early treatment with the VIASKIN Peanut Patch can alter peanut allergy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves centanafadine for ADHD in children, adolescents, and adults
2
Ensitrelvir now available in US for COVID-19 postexposure prophylaxis
3
FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring
4
Jeff Temple, PhD: Focus on healthy habits, not screen time alone
5